Oxycodone Hydrochloride

Known as: hydrochloride oxycodone, oxycodone hcl, 4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride 
The hydrochloride salt of oxycodone, a methylether of oxymorphone and semisynthetic opioid agonist with analgesic and antitussive properties… (More)
National Institutes of Health

Related topics

Related topics

20 relations
Abuse-Deterrent 12 HR Oxycodone Hydrochloride 80 MG Extended Release Oral Tablet [Oxycontin]Acetaminophen 325 MG / Oxycodone Hydrochloride 5 MG Oral Tablet [Percocet]Acetaminophen 325 MG / Oxycodone Hydrochloride 5 MG Oral Tablet [Roxicet]Aspirin 325 MG / Oxycodone Hydrochloride 4.5 MG / oxycodone terephthalate 0.38 MG Oral Tablet
(More)

Narrower (5)

CombunoxOxycontinPercocetPercodan
(More)

Broader (1)

Oxycodone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
UNLABELLED Oxycodone hydrochloride controlled-release, also known as extended-release oxycodone (ER oxycodone), was reformulated… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
INTRODUCTION Two randomized, double-blind, placebo-controlled studies in acute and chronic pain treatment, powered to assess… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III…
OBJECTIVES The primary objective of this study was to assess the efficacy and tolerability of tapentadol immediate release (IR… (More)
Is this relevant?
2009
2009
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
BACKGROUND Oxycodone is a mu-opioid receptor agonist that is metabolized mainly in the liver by cytochrome P450 3A and 2D6… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2007
2007
Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain.
BACKGROUND AND OBJECTIVE Oxycodone is a semisynthetic opioid analgesic drug classed as a strong opioid. The controlled-release… (More)
Is this relevant?
2004
2004
Incidence of constipation associated with long-acting opioid therapy: a comparative study.
BACKGROUND Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently… (More)
Is this relevant?
1997
1997
Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone.
BACKGROUND For patients with chronic pain, treatment with oral analgesics is considered most convenient and feasible. Sometimes… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
1. Oxycodone is a strong opioid agonist that is currently available in immediate-release (IR) formulations for the treatment of… (More)
  • table 1
  • figure 2
  • table 2
  • figure 3
  • table 3
Is this relevant?
1992
1992
Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.
The single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone have been determined in patients with… (More)
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Morphine and oxycodone hydrochloride in the management of cancer pain.
In a double-blind crossover study, morphine and oxycodone hydrochloride were administered to 20 patients who were experiencing… (More)
Is this relevant?